Related Experiment Video
Updated: Nov 29, 2025
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and
Thiruganesh Ramasamy1, Xucai Chen1, Bin Qin1
1Center for Ultrasound Molecular Imaging and Therapeutics, Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, United States of America.
Abstract:
Signal transducer and activator of transcription-3 (STAT3) is an oncogenic transcription factor implicated in carcinogenesis, tumor progression, and drug resistance in head and neck squamous cell carcinoma (HNSCC). A decoy oligonucleotide targeting STAT3 offers a promising anti-tumor strategy, but achieving targeted tumor delivery of the decoy with systemic administration poses a significant challenge. We previously showed the potential for STAT3 decoy-loaded microbubbles, in conjunction with ultrasound targeted microbubble cavitation (UTMC), to decrease tumor growth in murine squamous cell carcinoma. As a next step towards clinical translation, we sought to determine the anti-tumor efficacy of our STAT3 decoy delivery platform against human HNSCC and the effect of higher STAT3 decoy microbubble loading on tumor cell inhibition. STAT3 decoy was loaded on cationic lipid microbubbles (STAT3-MB) or loaded on liposome-conjugated lipid microbubbles to form STAT3-loaded liposome-microbubble complexes (STAT3-LPX). UTMC treatment efficacy with these two formulations was evaluated in vitro using viability and apoptosis assays in CAL33 (human HNSCC) cells. Anti-cancer efficacy in vivo was performed in a CAL33 tumor murine xenograft model. UTMC with STAT3-MB caused significantly lower CAL33 cell viability compared to UTMC with STAT3-LPX (56.8±8.4% vs 84.5±8.8%, respectively, p<0.05). In vivo, UTMC with STAT3-MB had strong anti-tumor effects, with significantly less tumor burden and greater survival compared to that of UTMC with microbubbles loaded with a mutant control decoy and untreated control groups (p<0.05). UTMC with STAT3 decoy-loaded microbubbles significantly decreases human HNSSC tumor progression. These data set the stage for clinical translation of our microbubble platform as an imaged-guided, targeted delivery strategy for STAT3 decoy, or other nucleotide-based therapeutics, in human cancer treatment.
Insights
Ultrasound targeted microbubble cavitation effectively delivers Signal transducer and activator of transcription-3 (STAT3) decoys to inhibit head and neck squamous cell carcinoma (HNSCC) growth. This targeted therapy shows significant anti-tumor effects, paving the way for clinical translation in cancer treatment.
Area of Science:
- Oncology
- Biotechnology
- Nanomedicine
Background:
- Signal transducer and activator of transcription-3 (STAT3) is a key oncogenic factor in head and neck squamous cell carcinoma (HNSCC) development and progression.
- Targeted delivery of STAT3 decoy oligonucleotides is crucial for effective anti-tumor therapy but remains a challenge.
- Previous studies demonstrated the potential of STAT3 decoy-loaded microbubbles with ultrasound targeted microbubble cavitation (UTMC) in murine models.
Purpose of the Study:
- To evaluate the anti-tumor efficacy of a STAT3 decoy delivery platform using microbubbles against human HNSCC.
- To compare the efficacy of two STAT3 decoy loading methods: cationic lipid microbubbles (STAT3-MB) and liposome-conjugated lipid microbubbles (STAT3-LPX).
- To assess the impact of higher STAT3 decoy loading on tumor cell inhibition and overall anti-cancer effects.
Main Methods:
- In vitro studies utilized CAL33 human HNSCC cells to assess viability and apoptosis after UTMC with STAT3-MB and STAT3-LPX.
- In vivo efficacy was evaluated in a CAL33 tumor murine xenograft model.
- Comparisons were made against UTMC with mutant control decoys and untreated controls.
Main Results:
- UTMC with STAT3-MB significantly reduced CAL33 cell viability compared to UTMC with STAT3-LPX (56.8±8.4% vs 84.5±8.8%, p<0.05).
- In vivo, UTMC with STAT3-MB demonstrated significant anti-tumor effects, reducing tumor burden and improving survival (p<0.05).
- STAT3-MB formulation showed superior efficacy over STAT3-LPX and control groups.
Conclusions:
- UTMC with STAT3 decoy-loaded microbubbles is an effective strategy for decreasing human HNSCC tumor progression.
- The STAT3-MB formulation offers a promising platform for targeted delivery of nucleotide-based therapeutics.
- This approach represents a significant step towards clinical translation for image-guided cancer therapy.
